Paul Bolno, Wave Life Sciences CEO

Take­da, Wave Life Sci­ences re­vise their $230M R&D col­lab­o­ra­tion, drop­ping dis­cov­ery work

Three years af­ter Take­da paid a hefty down pay­ment on a re­search col­lab with Wave Life Sci­ences, the two part­ners have re­vised the pact.

The Cam­bridge biotech an­nounced a re­vi­sion to its deal with Take­da yes­ter­day — end­ing their al­liance on dis­cov­ery work. As part of the amend­ment, Take­da will pay Wave more than $22 mil­lion for re­search and pre­clin­i­cal ex­pens­es from the col­lab­o­ra­tion.

Back in 2018, Cam­bridge, MA-based Wave en­tered a mega-deal with Take­da. The deal was two-fold: Wave gave Take­da the op­tion to co-de­vel­op and co-com­mer­cial­ize pro­grams in Hunt­ing­ton’s dis­ease, amy­otroph­ic lat­er­al scle­ro­sis (ALS), fron­totem­po­ral de­men­tia, and spin­ocere­bel­lar atax­ia type 3. Take­da al­so had the right to li­cense sev­er­al of Wave’s pre­clin­i­cal pro­grams tar­get­ing CNS dis­or­ders, in­clud­ing Alzheimer’s and Parkin­son’s.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.